Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2007

View Archived Issues

Mucosal trivalent vaccine against botulism toxin identified at DOR BioPharma

Novel agents for metabolic disorders described in recent patents

Recent patents describe new compounds targeting cardiovascular diseases

New agents for treating disorders of hemostasis reported in recent patents

HyCAMP shows greater efficacy than Camptosar in metastatic colorectal cancer

New safety data presented on Riquent

ANAVEX 1-41 and ANAVEX 2-73 show potential in preclinical Alzheimer's studies

CuraGen completes sale of 454 Life Sciences to Roche

Genzyme to acquire Bioenvision

Ranbaxy acquires 13 derma products from BMS

New phase II trial for Panzem NCD with Temodar in recurrent GBM

Fx-1006A studied for familial amyloid polyneuropathy in phase II/III study

Talima Therapeutics closes new Series B funding round

Avexa receives grant to develop new generation of HIV antiviral drugs

Primary endpoint met in pivotal study of aztreonam lysine in cystic fibrosis

Takeda licenses BioWa's Potelligent technology for antibody development

Clinical utility, tolerability of desvenlafaxine demonstrated in major depression patients

Durable fibromyalgia responses seen with pregabalin

Clinical trials in urological diseases

Preclinical data on new drugs for pulmonary inflammatory diseases

Archexin cleared to begin phase II trial in renal cell carcinoma

New European trial studies Vascular Wrap

Protherics withdraws European application for Voraxaze

Torisel approved for advanced renal cell carcinoma

Telavancin begins European review for cSSTI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...